Related Experiment Video
Updated: Aug 4, 2025
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
1Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium; Laboratory of Experimental Medicine and Paediatrics (LEMP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; InflaMed Centre of Excellence, University of Antwerp, Antwerp, Belgium; Translational Sciences in Inflammation and Immunology, University of Antwerp, Antwerp, Belgium; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Antwerp University Hospital, Drie Eikenstraat 665, Edegem B-2650, Belgium.
Abstract:
Recent progress in our understanding of the pathogenic mechanisms that drive progression of nonalcoholic steatohepatitis as well as lessons learned from several clinical trials that have been conducted over the past 15 years guide our current regulatory framework and trial design. Targeting the metabolic drivers should probably be the backbone of therapy in most of the patients, with some requiring more specific intrahepatic antiinflammatory and antifibrotic actions to achieve success. New and innovative targets and approaches as well as combination therapies are currently explored, while awaiting a better understanding of disease heterogeneity that should allow for future individualized medicine.
Insights
Nonalcoholic steatohepatitis (NASH) treatment strategies are evolving, focusing on metabolic drivers and anti-inflammatory/antifibrotic actions. Future therapies may involve combination treatments and personalized medicine approaches for NASH patients.
Area of Science:
- Hepatology and metabolic disease research.
- Clinical trial analysis and regulatory science.
Background:
- Understanding nonalcoholic steatohepatitis (NASH) pathogenesis has advanced significantly.
- Fifteen years of clinical trial data inform current therapeutic strategies and trial designs.
Purpose of the Study:
- To review current regulatory frameworks and trial designs for NASH.
- To discuss potential therapeutic strategies targeting metabolic, inflammatory, and fibrotic pathways in NASH.
- To highlight the need for personalized medicine in NASH treatment.
Main Methods:
- Review of recent scientific literature on NASH pathogenesis.
- Analysis of outcomes and lessons learned from completed NASH clinical trials.
- Discussion of emerging therapeutic targets and combination therapy approaches.
Main Results:
- Current NASH therapy frameworks emphasize targeting metabolic drivers.
- Additional intrahepatic anti-inflammatory and antifibrotic interventions are crucial for treatment success in some patients.
- Innovative targets, combination therapies, and personalized medicine are under exploration.
Conclusions:
- Therapeutic strategies for NASH should primarily address metabolic dysfunction.
- Combined approaches incorporating anti-inflammatory and antifibrotic actions are necessary for complex cases.
- Further research into NASH heterogeneity is essential for developing individualized treatment plans.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:24Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:26Atherosclerosis III: Management
01:26Nephrotic Syndrome II : Assessment and Medical Management